Aim:To determine the 0.1 percent topical sodium diclofenac analgesic effect on the retina during laser photocoagulation. Study Design: Arandomized prospective control study. Place and Duration:In the Ophthalmology department of Hayatabad Medical complex Peshawar and Woman Medical and Dental College, Abbottabad for duration of six months from November 2020 to April 2021. Methods:The study included 90 people with 47 cases of proliferative diabetic retinopathy who had two sessions of pan-retinal photocoagulation (group A) as well as 43 people with non-proliferative diabetic retinopathy who received bilateral grid treatment (group B) (group B).sodium chloride 0.9% or Sodium diclofenac 0.1% topical drops were instilled 30–135 mints formerly to treatment with laser in a concealed fashion.When a patient had 2 sessions, the alternative medicine was administered in the second session. The visual analogue scale was castoff to measure the amount of pain immediately after the laser therapy (VAS). The findings were subjected to statistical analysis Results: In 84/90 sessions, patients in A grouptestifiedpain (93.3 percent). When 0.1 percent sodium diclofenac drops were instilled, the mean stated grade of pain was 47.8 percent, and when 0.9 percent sodium chloride drops were instilled, the mean reported degree of pain was 53.3 percent. Only 14/60 sessions (23.3 percent) of patients in group B reported pain, and pain levels varied from 10% to 60% depending on the kind of drops administered. There was no link between pain intensity and the time it took to go from applying the drops to laser therapy (30–135 minutes) or the average energy level utilized (100–500 mW) in either group. Conclusion:Pan-retinal photocoagulation should be performed after the administration of sodium diclofenac 0.1 percent, which is an excellent pain reliever.
Aim: To govern the intravitreal injection effect of triamcinolone (IVT) on visual acuity in patients with ischemic central retinal vein obstruction (CRVO). Study Design: A randomized clinical trial. Methods:The patients with ischemic event of CRVO less than amonth who were referred to the ophthalmology departmentof Hayatabad Medical Complex, Peshawar and Woman Medical and Dental College, Abbottabad. Patents were included for the duration from March 2021 to August 2021.Inclusion criteria were: < one month duration of CRVO, normal intraocular pressure, no symptoms of hypertensive or diabetic retinopathy, history of eye surgery or laser therapy, and no vascular disease. Patients were randomized into 2 groups: control group (no injection) and intervention group (0.1 cc IVT injection). Follow-up is scheduled for 1, 2, 3 and 6 months after injection for all patients. The main outcomes of the study were evaluated and used for statistical analysis were SPSS software version 21.0 ion test-t statistical test. Results:70 patients (36 men and 34 women) participated in the study. 62.1 ± 8.9 was the mean age of patients (range: 30-80). The time of symptoms was 20 ± 4.9 days in the control group and in the IVT group; duration was 19 ± 6 days (p = 0.65). All subjects had symptoms of ischemic CRVO. The IVT group has mean baseline visual acuity of 1.80 ± 0.19 logMAR and in the control group; it was 1.91 ± 0.08 logMAR (p = 0.1). The enhancement in VA in the IVT group was better after one month as compared to the control group (p = 0.018); though, this variance was not significant in other control studies. Also, before and after injection; the alteration in IOP was not significant (p = 0.802). Conclusions: This analysisexhibited that triamcinolone intravitreal injection had no substantial long-term outcome on visual acuity among CRVO patients. Keywords:Triamcinolone, Central Retinal Vein Occlusion
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.